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Conversion of SB 2035804nsensitive MAP kinase family members 
to drug-sensitive forms by a single amino-acid substitution 
Patrick A Eyersl, Molly Craxton *, Nick Morricel, Philip Cohen’ and Michel Goedert* 
Background: Specific inhibitors of protein kinases have great therapeutic 
potential, but the molecular basis underlying their specificity is only poorly 
understood. We have investigated the drug SB 203580 which belongs to a 
class of pyridinyl imidazoles that inhibits the stress-activated protein (SAP) 
kinases SAPK2a/p38 and SAPK2b/p38P2 but not other mitogen-activated 
protein kinase family members. Like inhibitors of other protein kinases, 
SB 203580 binds in the ATP-binding pocket of SAPK2aIp38. 
Results: The SAP kinases SAPKl y/JNKl, SAPKB and SAPK4 are not 
inhibited by SB 203580, because they have methionine in the position 
equivalent to Thr106 in the ATP-binding region of SAPK2a/p38 and 
SAPK2b/p38P2. Using site-directed mutagenesis of five SAP kinases and the 
type I and type II TGFP receptors, we have established that for a protein kinase 
to be inhibited by SB 203580, the sidechain of this residue must be no larger 
than that of threonine. Sensitivity to inhibition by SB 203580 is greatly 
enhanced when the sidechain is even smaller, as in serine, alanine or glycine. 
Thus, the type I TGFP receptor, which has serine at the position equivalent to 
Thr106 of SAPK2a/p38 and SAPK2b/p38P2, is inhibited by SB 203580. 
Conclusions: These findings explain how drugs that target the ATP-binding 
site can inhibit protein kinases specifically, and show that the presence of 
threonine or a smaller amino acid at the position equivalent to Thri 06 of 
SAPK2a/p38 and SAPK2b/p38P2 is diagnostic of whether a protein kinase is 
sensitive to the pyridinyl imidazole class of inhibitor. 
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Introduction 
Prorcin kinases form one of the largest families of protcins 
cncodcd in the human genome, and these enzymes ha\x 
pivotal roles in almost all aspects of cell regulation. Abnor- 
mal protein phosl-‘horFl3tion is the cause or consequcncc of 
man)- diseases and, for this reason, protein kinases ha1.c 
bccomc attractive targets for drug thcrap),. Several rela- 
ti\dy specific inhibitors of these enzymes ha\~ been 
clevcloped that have therapeutic potential for the treatment 
of cancer. diabetes. hi pertcnsion and inflammation [l-.3]. A 
class of pyridinyl imidazoles suppresses the s);nthesis (and 
some of the actions) of pro-inflammatory cytokines, and 
shows promise for the trutment of rheumatoid arthritis and 
other chronic inflammatory conditions [a]. ‘I’hcse pyridinyl 
imidazoles arc remarkably specific inhibitors of stress-acti- 
vatcd protein (SAP) kinasc 21 (SAPIQa, also termed p.38, 
KK and (:SRPZ) and SAP kinnse 2b (SAPKZh, also tamed 
p.38~2) [S,O] and ha1.c been ~cxd to identify physiological 
srlbstratcs of these protein !&uses, such as the protein 
kinasec h1AI’K.W kinascs 2/3 and hlnkl/Z, and sc\xxil 
transcription factors (rc\ic\ved in 171). 
protein (hlhl’) kinasc family (6.X-1 11. Other mcmbcrs of 
this family, how3 cr. u hose amino-acid scquciicch arc 
-IO-(iO%’ identical to SAPKZa/p.iX md S;\I’KZh/p38~2 arc 
not inhibit4 by the 13) ridinyl imitiadc\ SR 20.%5X0 or 
SLS 202190. ‘I‘hcsc cii~ymcs inclkidc S.U’Kl (or JNK), of 
Lvhich there ;irc 3 number of closclv rclatcd isoforms that 
phosphor) larc the transactivation doAiin of c-Jun [5.1.2,1.3] 
and the more rcccntl) idcntificti SlWK.3 (also callal 
ERIC6 and p3Xy) (l-L171 and SZPKl (dso cdlcd p.388) 
[C~,10.18,1C~] \vhosc physiological siilvxraw arc r~nli~iou~~i. 
SR 2035X0 hinds S:ZPK2a/p3H conipctiti\cly v ith .YI’I’ [70]. 
and the determination of the tllrcc-dimensional strtaurc of 
SAPKL/p38 in ;I complex \vith ;I closcl~ rclatcd p) ridin) I 
imidazolc has cstal>lishcd that thcsc drugs invxt into the 
A’I’P-t,incling pocket of S.WUi/p3X [21.X]. ‘l’hcsc ;m:ily- 
ses also rtxwlccl that the _I-tluorophcn~ I rinx of the cirll,q 
dots not mahc cont;icI \\ith rcsidlles in the :\‘l‘l’-t)indin,q 
pocket that interact directI> \! ith :Vl’t’. One rcsici(lc nwr 
the l-fllwrophcnyl ring is ‘I‘hrlM xd mutation c)f this 
residtic to methionine makes S:\I’KZa/p.JS inscnsiti\ c ro 
the di-ug [32]. ‘I’hrlM is conser\cd in S.~l’KZh/piX~2. but is 
replacccl by mcthioninc in S,~l’Kly/~~Kl. SAPK.3 aid 
SAt’K4 (Figure 1 ). \Ye thcrcforc cumincd the role pla)cci 
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Figure 1 
(a) 
MAP kinase family member Sequence surrounding ThrlO6 
* 
SAPK2a/p38 FNDVYLVTHLMGADL 
* 
SAPK2b/p38Pz FSEVYLVTTLMGADL 
* 
SAPK3 FTDFYLVMPFMGTDL 
* 
SAPK4 FYDFYLVYPFMQTDL 
* 
SAPKly/JNKl FQDVYIVMELMDANL 
* 
SAPKlP/ JNKZP FQDVYLVWELMDANL 
* 
WAPKZ/ERK2 MKDVYIVQDLMETDL 
0.d 
Other protein kinases Sequence surrounding Thr106 
* 
Type II TGFP receptor GKQYWLITAFHAKGN 
* 
EGF receptor TSTVQLITQLMPFGC 
* 
PDGF receptor GGPIYIITEYCPYGD 
* 
Lck QEPIYIITEYNENGS 
* 
Src EEPIYIVTEYMSKGS 
* 
Abl EPPFYIITEFMTYGN 
* 
Type I TGFP receptor WTQLWLVSDYHEHGS 
* 
MAPKl/ERKl (D.d.iscoideum) FEDYYIVSELMDTDL 
??
SAPK2a/p38 (C. elegans) IEDVYFVSMLMGADL 
* 
SAPK2b/p38& (C.elegans) LNNVYFVSVLMGSDL 
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Amino-acid sequences surrounding Thr106 in 
SAPK2aIp38 and SAPK2b/p38P2 (the 
residue that confers sensitivity to SB 203580). 
(a) Human MAP kinase family members. 
(b) Protein kinases with threonine or serine in 
the position equivalent to Thr106 of human 
SAPK2a/p38. The residues in the position 
equivalent to Thr106 in human SAPK2alp38 
are marked by an asterisk. 
! 
9 
by the threonine/methionine residue in conferring sensitiv- 
ity or resistance to the pyridinyl imidazole drugs on these 
and other protein kinases. SAPKl/JNKl, SAPK3 and 
SAPK4 became sensitive to SB 203.580 following mutation 
of this methionine to threonine or a smaller amino acid. 
The presence of serine or threonine at this position was also 
found to be diagnostic of whether more distantly related 
protein kinases are sensitive to inhibition by SB 203580. 
Results 
Inhibition of SAP kinase mutants by SB 203580 
SAPKS and SAPK4 both became sensitive to SB 203580 
when methionine in the equivalent position of ThrlO6 in 
SAPKZa/p38 was changed to threonine (Figure 2). Further 
mutagenesis to a variety of other residues revealed that a 
sidechain smaller than that of threonine, as in serine, 
alanine or glycine, made SAPK3 more sensitive to the 
drug (I(&, = lo-50 nM), whereas inhibition was extremely 
poor when a large residue, such as glutamine, was present 
at this position (Table 1). Glutamine is found at this posi- 
tion in MAP kinase family members MAPKl/ERKl and 
MAPKZ/ERKZ. The MetlO9+Ala and MetlO9+Gly 
mutants of SAPKS had the same K,,,/K,,, values as the 
wild-type enzyme (data not shown). 
SAPK4, SAPKZa/p38 and SAPKZb/p3@2 also became 
more sensitive to SB 203580 when glycine or alanine was 
present at this position (IC,5, = 15-30 nM; Figure 2). 
Human wild-type SAPKZa/p38 was inhibited about 
tenfold more potently than human wild-type SAPKZb/ 
p38p2 or the threonine mutants of SAPK3 and SAPK4 
(Figure 2). The sensitivities of all these enzymes to 
SB 203.580 became similar, however, after mutation of 
Thr106 to glycine or alanine (Figure 2). The alanine 
mutants were inhibited more strongly than the glycine 
mutants, suggesting that the size of the alanine sidechain 
is optimal for inhibition by SB 203580. Even though 
SAPKZa/p38 and SAPKZb/p3802 are less similar to the 
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Figure 2 
) (a) 120 
= 
20 
iAPK4 Ml07 
(b) 120 
SAPK3 
100 
20 
0 
Concentration of SB 203580 (NM) 
Concentration of SB 203580 (uM) 
W 120 
Inhibition of wild-type and mutant SAPK2a/p38, SAPK2b/p38P2, 109, respectively. (c) Wild-type SAPK2aip38 has a threonine residue 
SAPKB and SAPK4 by SB 203580. The effect of the drug on the wild- at position 106 and is inhibited by SB 203580 with an IC,, value of 
type enzymes is shown by the closed circles and its effect on mutant 0.08 PM. Thrl OG+Met SAPK2a/p38 is still inhibited by SB 203580, 
enzymes by open symbols. Mutations are designated using single- but the IC,, value has increased to 100 PM. (d) Wild-type 
letter amino-acid code (for example, Ml 07T, Met1 07-tThr). SAPK2b/p38P2 has a threonine residue at position 106 and is 
(a, b) Wild-type SAPK4 and SAPKB are resistant to SB 203580, inhibited by SB 203580, with an IC,, value of 1 PM. Thrl OG-+Met 
because these kinases have methionine residues at positions 107 and SAPK2b/p38!32 is resistant to SB 203580. 
100 
20 
0 
Concentration of SB 203580 (PM) 
3APK2b Tl06M 
0.001 0.01 0.1 1 10 
Concentration of SB 203580 (PM) 
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isoforms of SAPKl/JYK (40% identity) than to SAPKS or SAPK2a/p38 (Figure 2). After mutation to alanine, 
SAPK3 (60% identity) [8-191, SAPKly/JiXKl became sen- howe\zr, SAPKly/JNKl n-as inhibited by SB 203.580 at 
sitive to inhibition by SB 203.580 when iLlet108 was submicromolar concentrations (Figure 3). SAPKly/JNKl 
mutated to threonine (Figure 3). The IC,i,, value (10 pR1) differs from other SAP kinases by the presence of 
for the l\letl08+Thr SAPKly kinase was 30- to SO-fold isoleucine at position 106 instead of Ieucine [13]. \Vhen 
higher than for SAPK2b/p3@2 or the threonine mutants of residue 106 was changed to leucine in the wild-type 
SAPK3 or SAPK4, and 500-fold higher than for wild-type enzyme. SXPKly/JNKl u’as inhibited to some extent by 
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Table 1 Figure 3 
Effect of mutating Met109 on the sensitivity of SAPK3 to 
SB 203580. 
Residue at position 109 IC,, value (PM) 
- 
Methlonine >lOO 
Phenylalanlne >lOO 
Lysine 55 
Glutamine 50 
Leucine 45 
Glutamate 45 
Threonine 0.3 
Senne 0.05 
Glycine 0.03 
Alanine 0.01 
Site-directed mutagenesis was used to change residue 109 in SAPK3 
from methionine to one of nine other amino acids. 
SB 203.5#0, with an I&, value of 50 pnl (Figure 3). \Yhen 
IlelOh was changed to leucine in the hletl(M+Thr and 
hlctlO8-+Ala mutants, SAF’Kly/JNKl was strongly inhib- 
ited by SB 203.5X0, with an IC,,, value of 30 nnl for the 
IlelO6+I~eu nletlO8+Ala SAPKly/JNKl (Figrlrc 3). 
‘I’hesc results demonstrate that residue 10X is the major 
determinant for inhibition of SAPKly/JNKl by pyridinyl 
imidazolcs and that rcsiduc 106 plays a minor role. 
0.001 0.01 0.1 1 10 
Concentration of SB 203580 (FM) 
120 
SAPKl y 
a 
lookF\ llO6L 
Inhibition of Lck and the type II TGFP receptor by 
SB 203580 
ThrlO6 of SAPK2a/p38 is located in subdomain 11. of the 
kinase catalytic domain (Figure 1). Examination of the 
sequences of other protein kinases re\ caled that a bulk) 
hydrophobic rcsiduc is almost always found at this posi- 
tion. Ne\,crthcless, a small number of protein kineses do 
ha\.c threonine at this position, such as the type II trans- 
forming growth factor p (‘I’GFP) receptor (a scrine/threo- 
nine protein kinase). members of the Src family of 
protein tyrosine kinases and some receptor protein tyro- 
sine kinascs, such as the epidermal growth fxtor (EGF) 
and platclct-derived growth factor (PIXF) receptors 
(Figure 1). In order to determine if the prcsencc of thrc- 
oninc at this position is diagnostic of sensiti\,ity to 
SH 2035X0, we examined Lvhcther the type II ‘IGFP 
rcccptor [23] and Lck (a Src family member) [24] were 
inhibited by this drug. These csperimcnts rcvealcd that 
both kinascs were inhibited by SB 203580, \+ith IC5,, 
\xltles of 20 phi (Lck) and 40 ~1.21 (t)pe II ‘IGFP reccp- 
tor) (Figure -la). \Vhcn Thr32.5 in the type II TGFP 
receptor was changed to methionine, the cnzymc 
became insensitive to the drug (I;igure 4a). By contrast, 
N hen Thr3Z.5 was changed to alaninc, the type II ‘TGFP 
receptor was inhibited by SB 203.580 with an ICio of 
1 l1\1 (Figure la). In addition, SK&F 105809, a closeI> 
related pyridinyl imidazole that dots not inhibit 
ShPK2a/p38 [.5], did not inhibit an) of the type II ‘I‘GFP 
receptor constructs (data not shown). The type II TGFB 
receptor was inhibited by SR 203580 with the same IC,,, 
L 
Y I 
0.001 0.01 0.1 1 10 100 
Concentration of SB 203580 (PM) 
Chemlstv & B~olonv 
Inhibition of wild-type and mutant SAPKly/JNKl by SB 203580. The 
effect of the drug on the wild-type enzyme is shown by the closed 
circles and its effect on the mutant enzymes by open symbols. 
Mutations are designated using single-letter amino-acid code. Wild- 
type SAPKl y/JNKl is resistant to SB 203580, because it has a 
methlonine residue at position 108 and an isoleucine residue at 
position 106. The kinase becomes sensitive to SB 203580 when 
Met1 08 is mutated to threonine, and even more sensitive when 
Met1 08 is mutated to alanine. 
\ralue whether it was assayed using autophosphorylation 
(1;igure 4a) or using histone HZB as a substrate (data not 
shown). These results establish that the sensitivity of the 
type II TGFB receptor to SB 203580 is conferred by 
ThrSZ.5 in subdomain IV. 
100 
\ 
0 
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Figure 4 
(a) 120 
Type II 
60- 
T325A 
\ 
(b) 120 
Concentration of SB 203580 (PM) 
0 I I 
0.1 1 10 100 
Concentration of SE 203580 (FM) 
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Inhibition of the type I TGFP receptor and the type II TGFP receptor 
by SB 203580. (a) The effect of SB 203580 on the native type II 
TGFP receptor is shown by closed circles and its effect on the 
mutant enzymes by open symbols. The type II TGFP receptor has a 
threonlne residue at position 325 and is inhibited by SB 203580 
with an IC,, value of 40 FM. The Thr325+Ala mutant IS inhibited 
with an IC,, value of 4 ,uM, whereas the Thr325+Met mutant is 
resistant to SB 203580. (b) The effect of SB 203580 on the native 
type I TGFP receptor is shown by closed circles and its effect on the 
Ser280+Met mutant by open circles. The type I TGFP receptor has 
a serine residue at position 280 and is inhibited by SB 203580 with 
an IC,, value of 20 PM. Replacement of this serine residue with 
methionine increases the IC,, value to > 100 PM. Mutations are 
designated using single-letter amino-acid code. 
Inhibition of the type I TGFP receptor by SB 203580 
\‘ery few protein kinascs ha\x swine at the ccl~~iulent 
position of ‘I‘hrlO6 of S_M’K3a/lx3X (for insrancc a tn:~n- 
malian type I ‘I’GFp receptor [25]. S:Z1’KL;~/p3ti and 
S:ZPK2b/l~3X~2 frolll (kwf 0hINlii.s dty/us [ (knban li 
accession numbers: 132KW1 and 3702-W] and \IhI kinasc 
from IMy.Vdiwn c/hA-w~~~ [%I: 1:igtire 1). In order to 
determine if the presence of scrinc at this position confcl-s 
sensitivity to SR 203.5X0. cvc cumincd \\hether the type I 
‘I’GFP receptor 1~1s inhibited I>) this cornlx~~~~~d. As shcnvn 
in Figure -lb. the type I ‘I’GF~ rcccptor \~a sensiti\ c to 
inhibition by St3 303580. \\,ith iiii I(:,j,, \ aluc of 30 likt. B! 
contrast, \vhcn Scr-780 in the type I ‘IY;ITp rcccptor v as 
changed to mcthioninc, the cnqnie Ixxamc inscnsiti\ c to 
the drug. ‘I‘hcsc findings are consistent ~1 ith the mutagen- 
csis study on SXI’K3 which shoucd that the P\IctlOc~+Scr 
mutant ux more scnsiti\ e to inhil,ition t)\ St3 2035X0 than 
the 2lctlOO+‘I’hr mutant (‘I’ablc 1 ). 
Discussion 
‘I’hc prcscnt findings demonstrate thiit inhibition of 
S;\l’ICa/pX and SAPK2b/$tl~Z hy the p!ridin) I imida- 
zolc St3 203.580 depends on the six of the :rmino-acid 
residue at position 106 of the :\‘I‘P-binding region. LIlit;l- 
tion of rcsiduc 106 from threoninc to mcthioninc made 
S.WKLb/l&3~Z insensiti\xz to SR 20.3.iXO. It also rcndcrcti 
SXPUa/p3X almost completc:l~ resistant to SH 20.3.M3, in 
agrccmcnt \vith ;i lxx\ ious study [El. (~oii\ ersely, mut;1- 
tion of the cclui\alent residue in S;ZI’K.i and SAt’K-l from 
mcthionine to thrconinc rcndcrcd these cnn mcs sciIsi- 
tile to inhibition by SH ZO.iSHO. t:urthcr mutquicsis 
rc\wled that SAI’K3/l~.3Xy lxxamc more scnsitilc to the 
drug bhcii mcthionine \\xs rcplaccd I>) c\‘en smaltcr 
rcsiducs. such as serine, alaninc or glycine. S.AI’IGL/p.3S. 
StZPK~l~/p.W~Z and S.i\PK4/p.M also bccxnc mo\t scnsi- 
tiw to SR 20.15X0 u hen glycinc or alaninc \\;Is present at 
this position. ‘I’hese findings rule ollt the possibilit\ that 
the inhibition of S:WK_‘a/p.X and Sr\I’KZt~/p3S~7 rcstllts 
from the formation of ;I h>-drogen bond Ixtnccn the 
hydroxyl group of ‘I‘hrlM and the -I-tluorophcnyl moiety 
of SF3 203.580. .Uthough SAI’Kl/JKK. another h1.W kinasc 
family mcmlxr. is only 10% identical to S:\I’KZa/p3H and 
S.WKZb/p.?X~Z [ 1.31 it coulcl also bc con\ crtcd to ;I 
SK 2035X0-sensitive form t,\ mtiration of Zlctl OX to :I 
small amino acid. In order to optimist scnsiti\it) to the 
drug, hou CL cr. it \vas also ncccssary to change IlclM to 
the Icucinc residrie present at the cclui\alcnt position in 
other iL1.W kinasc family mcmlxrs. ‘I‘he latter result cotltd 
cxplain the reported inhibition of JiXK2bl and JNI\;ZPZ I,!, 
high concentrations of a 1’1 ridin)-t imickolc co~~~po~~~~tl 
1271, as these isoforms of S.WKl/JNK ha\c lciicinc at 
position 106 and methionine at position 10X [IA]. 
\Iost kno\vn mammalian protein kinascs ha\.c :I la-gc. 
hydrophobic rcsiduc at the position ccluiwlcnt to ‘I’hrlOh 
of Sr\I’KZa/p3X. t;en protein kinascs have thrconinc at 
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this position, and only two (the type I TGFP receptor and 
a type I activin receptor) have serine at this position. Two 
protein kinases that have threonine at the position equiv- 
alent to the SAPKZa/p38 ThrlOh (the type II TGFP 
receptor and the tyrosine protein kinase Lck) were found 
to be sensitive to inhibition by SB 203580, although the 
I%, values were 400-800 times higher than the I& 
value for SAPKZa/p38, indicating that residues other than 
the one equivalent to ThrlO6 of SAPKZa/p38 are 
involved in sensitivity determination. Nevertheless, sen- 
sitivity of the type II TGFP receptor to SB 203.580 was 
enhanced by mutagenesis of Thr325 to alanine, whereas 
it was abolished when Thr325 was changed to methion- 
ine. The type I TGFP receptor was inhibited more 
potently by SB 203580 than the type II TGFP receptor, 
consistent with the presence of the smaller serine residue 
at the position equivalent to Thr106 of SAPKZa/p38. 
!fThen studying phenotypic effects of SB 203.580 in cells, 
we have previously emphasized the importance of estab- 
lishing that these effects occur at a concentration similar to 
that which prevents the activation of SAPK2a/p38 in the 
same cell type [7]. The realisation that other protein 
kinases that contain serine or threonine at position 106 
equivalent are inhibited by SB 203.580 at concentrations 
above 10 @I makes this control mandator):. It will also be 
important to determine if all the reported effects of 
SB 203580 in mammalian cells are abolished by transfec- 
tion with a drug-insensitive form of SAPKZa/p38 or by the 
use of transgenic mice expressing an SB 203580-insensitive 
form of the SAPKZ/p38 protein kinase. 
No known protein kinase has glycine or alanine at the posi- 
tion equivalent to ThrlOh of SAPKZa/p38. If such enzymes 
exist, they can be expected to be potently inhibited by 
SB 203580. Recent work on non-receptor tyrosine kinases 
of the Src family has shown that the size of the residue 
equivalent to ThrlO6 in SAPKZa/p38 is also primarily 
responsible for determining the ability of protein kinases to 
accept Nb-substituted ATP analogues [28], further empha- 
sized the crucial role that this residue plays in determining 
the size of the ATP-binding pocket of protein kinases. 
Nearly all eukaryotic kinases belong to the same protein 
superfamily and their ATP-binding sites are similar. It 
therefore seemed unlikely that specific inhibitors of par- 
ticular protein kinases could be developed by targeting 
the ATP-binding region of these enzymes. Recent work 
describing a new class of receptor protein tyrosine kinase 
inhibitors suggests that this fear may be unfounded [29]. 
In addition, the present work indicates that remarkable 
specificity can be achieved if drugs that interact with the 
ATP-binding pocket carry an additional moiety that 
makes contact with residues outside this region. Our 
finding that sensitivity to SB 203580 can be gained by 
single amino-acid substitutions means that it should bc 
possible to use the same drug to identify the physiological 
roles of all RIAP kinase family members and perhaps 
other protein kinases. Replacement of 5% ild-type 
SAPKl/JNK isoforms. SAPK3 or SAPKl by drug-scnsi- 
tive forms of these enzymes in transgenic mice exprcss- 
ing a drug-resistant form of SAPKZa/p.M could also bc 
useful in addressing the physiological roles of these hlAP 
kinase family members. 
Finally. our results show that it is possible to predict 
whether or not a protein kinase Lvill be sensitive to inhibi- 
tion by this class of pyridinyl imidazoles simply by 
inspection of the amino acid at the position equivalent to 
ThrlO6 of S;\PKZa/p.lX in subdomain 11’ of the kinase 
catalytic domain. It might, therefore, be possible to idcn- 
tify lead inhibitors for some protein kinascs without an) 
high-throughput screening. 
Significance 
Protein kinases have important roles in many physio- 
logical processes, and they have become attractive 
targets for drug therapy because abnormal protein 
phosphorylation is an essential feature of many disease 
states. It is widely believed that specific protein-kinase 
inhibitors will constitute an important class of future 
drugs, permitting improved treatment of a large 
number of serious diseases, including cancer, diabetes 
and hypertension. 
It is, therefore, critical to understand the mechanisms of 
action of the few existing protein kinase inhibitors that 
have a high degree of specificity. The pyridinyl imida- 
zole SB 203580 is one such inhibitor. It inhibits stress- 
activated protein (SAP) kinase-2a (SAPK2a, also called 
~38) and SAP kinase-2b (SAPK2b, also called p3882), 
but not other members of the mitogen-activated protein 
(MAP) kinase family. SB 203580 has been used to iden- 
tify some of the physiological substrates and cellular 
functions of SAPK2alp38 and SAPK2b/p3@2. Here we 
show that for a protein kinase to be sensitive to 
SB 203580, the amino acid at the position equivalent to 
residue 106 of SAPK2a/p38 must be no larger than thre- 
onine, the sensitivity being greatly enhanced when this 
residue is even smaller, such as serine, alanine or 
glycine. The high degree of specificity of SB 203580 
results from the presence of a residue larger than threo- 
nine at this position in nearly all known protein kinases. 
These findings explain how drugs that target the ATP- 
binding site can inhibit protein kinases specifically and 
show that it is possible to predict whether or not a 
protein kinase will be sensitive to inhibition by this class 
of pyridinyl imidazoles simply by inspection of the amino 
acid at the position equivalent to Thr106 of 
SAPK2a/p38 in subdomain IV of the kinase catalytic 
domain. Our data should help to facilitate the rational 
design of specific protein-kinase inhibitors. 
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Materials and methods 
Site-directed mutagenesis and expression of protein kinases 
The open reading frame of human SAPK2a/p38 (CSBPP isoform) 141 
was amplified by PCR from brain cDNA, verified by DNA sequencing 
and subcloned into M13. Full-length cDNA clones encoding human 
SAPKlyIJNKl, human SAPK2blp38P2, rat SAPKB and human SAPK4 
were also subcloned into Ml 3. Site-directed mutagenesis was used to 
change IlelO6 in SAPKI -$JNKl to leucine and/or Met1 08 to alanine or 
threonine; Thr106 in SAPK2a/p38 was changed to alanine, glycine or 
methionine; Thr106 in SAPK2b/p38P2 was changed to alanine, glycine 
or methlonine; Met109 in SAPKB was changed to alanine, glutamine, 
glutamate, glycine, leucme, lysine, phenylalanine, serine or threonine; 
Met107 in SAPK4 was changed to alanine, glycine or threonine. All 
mutations were verified by DNA sequencing. Following primer extension, 
the mutated cDNAs were subcloned into bacterial expression vectors 
pRSETB (Invitrogen) or pGEX4T-1 (Pharmacia) and expressed as His- 
tagged proteins (SAPKly/JNKl) or as GST-fusion proteins 
(SAPK2a/p38, SAPK2bIp38P2, SAPKB and SAPK4) in Escher;chia 
co/i BL21 (DE3) cells. Human Lck 1241 was expressed in Sf9 cells from 
a recombinant baculoviral vector. Site-directed mutagenesis was used 
to change Thr325 in the type II TGFP receptor [23] to methionine or 
alanine. Mutagenesis was carned out as described previously [30]. The 
carboxy-terminal 375 residues of the wild-type TGFP type II receptor 
and the corresponding mutants were expressed in f. co/i as GST-fusion 
proteins and purified on glutathione-Sepharose [31]. Site-directed muta- 
genesis was used to change Ser280 in the type-l TGFP receptor 1251 to 
methlonlne. The carboxy-terminal 356 residues of the wild-type and 
mutant type I TGFP receptors were expressed in E. co/i as GST-fusion 
proteins and purified on glutathione-sepharose. 
Protein kinase assays 
Wild-type SAPKly/JNKI and Its mutants were activated using bacteri- 
ally expressed SAPK klnase-1 (SKKl, also called MKK4 or SEKl), 
which had been activated by MEK kinase-1 and assayed at 30°C in the 
presence and absence of the indicated concentrations of SB 203580 
using GST-ATF2(19-96) as substrate. Wild-type SAPK2a/p38, 
SAPK2bIp38P2. SAPKB and SAPK4 and their respective mutants 
were punfied on glutathione-sepharose and activated by a partially 
active mutant of human SAPK kinase-3 (SKK3, also called MKKG), in 
which Ser274 and Thr278 had been mutated to aspartate. This consti- 
tutlvely active SKK3/MKK6 mutant was expressed as a maltose-binding 
protein fusion protein In E. co/i and purified on an amylose resin. Each 
SAP klnase was assayed at 30°C in the presence and absence of the 
Indicated concentrations of SB 203580 using myelin basic protein as 
substrate, as described previously for MAPKP/ERKP kinase [32]. 
Mutants of SAPKl-$JNKl, SAPK2a/p38, SAPK2b/p38P, SAPKB and 
SAPK4 were activated at the same rates and to the same specific 
activltles as the wild-type enzymes. Human Lck was assayed using the 
peptide KVEKIGEGTYGVVYK, in the presence and absence of the 
Indicated concentrations of SB 203580. The type II TGFP receptor 
and its mutants were assayed at 30°C in the presence and absence of 
SB 203580 or SK&F 105809 by the rate of autophosphorylation or 
using histone H2B (0.1 mg/ml) as substrate. The mutants of the type II 
TGFP receptor had the same specific activity as the wild-type enzyme. 
The type I TGFP receptor was assayed by the rate of autophosphoryla- 
tion at 30°C in the presence or absence of the indicated concentra- 
tions of SB 203580. The concentration of ATP in all assays was 
0.1 mM. SB 203580 was purchased from Calbiochem. 
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